The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 23, 2018

Filed:

Oct. 31, 2016
Applicant:

Health Innovation Ventures B.v., Maastricht, NL;

Inventors:

Jeffrey Bruce Smaill, Auckland, NZ;

Adam Vorn Patterson, Waiheke Island, NZ;

Amir Ashoorzadeh, Auckland, NZ;

Christopher Paul Guise, Auckland, NZ;

Alexandra Marie Mowday, Auckland, NZ;

David Francis Ackerley, Wellington, NZ;

Elsie May Williams, Wellington, NZ;

Janine Naomi Copp, Nelson, NZ;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07F 9/09 (2006.01); C07C 255/58 (2006.01); C07C 309/66 (2006.01); C07C 317/48 (2006.01); C07D 295/13 (2006.01); C07D 295/192 (2006.01); C07C 309/69 (2006.01); C07C 317/36 (2006.01); C07D 295/104 (2006.01);
U.S. Cl.
CPC ...
C07F 9/09 (2013.01); C07C 255/58 (2013.01); C07C 309/66 (2013.01); C07C 309/69 (2013.01); C07C 317/36 (2013.01); C07C 317/48 (2013.01); C07D 295/104 (2013.01); C07D 295/13 (2013.01); C07D 295/192 (2013.01); C07F 9/091 (2013.01);
Abstract

The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds.


Find Patent Forward Citations

Loading…